Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms

Basit Öğe Kaydı
dc.authorid0000-0002-0947-9498
dc.contributor.authorDüğeroğlu, Harun
dc.contributor.authorÖztürk, Mustafa
dc.contributor.authorAtmaca, Murat
dc.contributor.authorSeven, İsmet
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:26Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:26Z
dc.date.issued2014
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractObjective: To investigate the effects of mesterolone on prostate in patients treated for aging male syndrome.Methods: The cross-sectional study was conducted from June to September, 2009, at endocrinology and metabolism department of Yuzuncu Yil University, Van, Turkey, and comprised patients with symptoms of aging male syndrome and/or low testosterone. They were given mesterolone 50mg/day per oral for two months. Aging Male Symptoms and International Prostate Symptom Score questionaires and prostate-related quality of life scores were completed and prostate ultrasonography (USG) was performed before and after the treatment. Total testosterone, free testosterone, gonadotropins, estradiol, prolactin, sex-hormone binding globulin, as well as total and free prostate-specific antigen were also studied.Results: Of the 34 patients in the study, 22(64.70%) had their prostate volume increased, while 12(35.29%) had it decreased. The change, however, was not statistically significant (p<0.098). Mesterolone significantly improved Aging Male Symptoms, International Prostate Symptom and prostate-related quality of life scores (p<0.001). These improvements though significant were independent of the changes in prostate volume. Total testosterone, sexhormone binding globulin andestradiol decreased, while free testosterone showed no change (p<0.002, p<0.001, p<0.024, p<0.337). The fraction of free testosterone increased (p<0.001), while total and free prostate-specific antigen did not change (p<0.368 and p<0.841).Conclusion: Mesterolone proved to be a safe alternative in the treatment of Aging Male Syndrome. It also improved lower urinary tract symptoms and prostate-related quality of life.
dc.identifier.citationDüğeroğlu, H., Öztürk, M., Atmaca, M. ve Seven, İ. (2014). Mesterolone treatment of aging male syndrome improves lower urinary tract symptoms. Journal of the Pakistan Medical Association, 64(12), 1366-1369.
dc.identifier.endpage1369
dc.identifier.issn0030-9982
dc.identifier.issue12
dc.identifier.scopusqualityQ3
dc.identifier.startpage1366
dc.identifier.urihttps://hdl.handle.net/20.500.12511/774
dc.identifier.volume64
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherPakistan Medical Association
dc.relation.ispartofJournal of the Pakistan Medical Associationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAndropause
dc.subjectMesterolone
dc.subjectProstate
dc.titleMesterolone treatment of aging male syndrome improves lower urinary tract symptoms
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Ozturk, Mustafa-2014.pdf
Boyut:
82.33 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu